New York, June 4, 2026, 13:04 EDT
CRISPR Therapeutics AG shares surged in early afternoon U.S. trade Thursday, up 11.7% at $58.15. Investors moved into gene-editing stocks. The Nasdaq name hit an intraday high of $59.00. About 2.0 million shares traded, putting its market cap close to $5.6 billion.
Biotech stocks rallied beyond a single name. The SPDR S&P Biotech ETF gained 3.0%. Gene-editing stocks Intellia Therapeutics climbed 14.4%, Beam Therapeutics added 10.6% and Editas Medicine rose 9.4%. CRSP moved with the sector, not alone.
CRISPR Therapeutics shares jumped after the company talked at the Jefferies Global Healthcare Conference on June 3. Management was set for another spot at Goldman Sachs on June 9, according to the schedule. CRISPR’s calendar also showed a slot at William Blair’s Growth Stock Conference, so the investor circuit was busy for them during a packed week for healthcare meetings.
Deal activity gave some support. Eli Lilly agreed to pay up to $1.9 billion for rights to Ascidian Therapeutics’ RNA exon-editing tech in rare inherited kidney diseases, Reuters reported Wednesday. The move is another example of big drugmakers paying for genetic-medicine platforms. RNA editing works on RNA—the temporary genetic message in cells—instead of changing DNA.
Lilly’s deal with Ascidian “aimed to dramatically reduce the burden” of genetic kidney disease, CEO Michael Ehlers told Reuters. Daniel Rosan, chief business officer, said the “key advantage” was “not actually altering the patient’s DNA.” The comments show demand for gene editing, but also point to alternatives to CRISPR/Cas9 and its DNA-cutting method. Reuters
Casgevy is still CRISPR Therapeutics’ main commercial asset. The therapy, developed with Vertex Pharmaceuticals, targets sickle cell disease and transfusion-dependent beta thalassemia. It’s an ex vivo process: doctors edit the patient’s cells outside the body, then put them back. Vertex runs the global development, manufacturing and sales, with profits and costs split 60/40 between Vertex and CRISPR.
Casgevy pulled in $43 million in revenue for the first quarter of 2026, the company said. More than 500 people worldwide have started on the treatment. “2026 will be a defining year for CRISPR Therapeutics,” chairman and CEO Samarth Kulkarni said in May. CRISPR Therapeutics
Beyond Casgevy, investors are focused on the in vivo pipeline, with CTX310 in a Phase 1b study for lipid disorders. The company flagged second-half readouts for zugo-cel, its off-the-shelf cell therapy for autoimmune disease and blood cancers, and said it is moving CTX460 and CTX340 into the clinic.
Still, the stock comes with the typical biotech risk and Thursday’s surge doesn’t leave much margin if news disappoints. CRISPR posted a net loss of $122.9 million for the first quarter, and the company warns its experimental therapies might never finish trials or get regulatory clearance. If Casgevy demand lags, trial results are poor, or investors lose taste for loss-making biotech, the rally could fade fast.
CRSP has another test coming up: Will the stock keep its gains after conference week ends? With no fresh approval or pivotal readout expected right now, price action probably sticks to swings in gene editing sentiment, updates around Casgevy sales, and what management says on clinical updates expected in 2026.
